

1 **SUPPLEMENTAL MATERIALS**

2 **SUPPLEMENTAL MATERIALS**

3 **Supplemental Methods:**

4 *Biomarkers*

5 Samples were batch processed for measurement of high-sensitivity troponin I (hs-troponin;  
6 ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay), N-terminal prohormone b-type  
7 natriuretic protein (NT-pro-BNP; Roche Cobas 6000 Elecsys® proBNP II assay), and high-  
8 sensitivity c-reactive protein (hsCRP; ADVIA® Chemistry CardioPhase™ High Sensitivity  
9 C-Reactive Protein assay). Most participants had antibodies and additional markers measured at  
10 samples from two earlier time points (<90 days and 90-150 days after infection) including IL-6,  
11 interleukin 10 (IL-10), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL),  
12 monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFN - $\gamma$ ), and tumor necrosis  
13 factor alpha (TNF- $\alpha$ ), and SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin G  
14 (IgG) (18). These samples were assayed by Monogram Biosciences (South San Francisco, CA)  
15 using the Quanterix Simoa® platform with Simoa® Assay Kits from Quanterix Corporation  
16 (Billerica, MA) blinded with respect to patient and clinical information, and assay performance  
17 was consistent with manufacturers' specifications.

18 Hematocrits were collected immediately before CMR with patient sitting right outside the MRI  
19 suite.

20 *Cardiac MRI imaging sequences:*

21 The protocol consisted of acquisition of the following sequences after multiplane localizers prior  
22 to gadolinium injection: fast imaging employing steady state acquisition (FIESTA) cine in the  
23 axial short axis planes, pre-contrast T1 mapping sequences using the MOLLI 5-(3)-3 technique,  
24 as well as pre-contrast T2 mapping at the basal, mid, and apical short axis planes and T2 fat-  
25 saturated weighted black blood spin-echo images in the short axis plane. 8-10 minutes after  
26 intravenous gadolinium injection, phase sensitive inversion recovery (PSIR) late gadolinium  
27 enhancement imaging in short axis full stack, 4 chamber full stack, three slices of 2 chamber  
28 images, and post-contrast T1 mapping sequences were obtained. Inversion times were  
29 individualized to null the myocardium.

30 Arterys software was used for T1 and T2 mapping and ECV calculation using pre- and post-  
31 contrast MOLLI sequences.

32 *Cardiopulmonary Exercise Testing*

33 First, baseline ECG, blood pressure, and rest spirometry including maximum voluntary  
34 ventilation (MVV) were measured. We determined the work increase per 1 minute step based on  
35 the expected peak  $VO_2$  from the MVV for a goal 10 minute test, rounded to 5 Watts/min  
36 increments based on reported exercise (range 10-30W/min) in accordance with guidelines.(58)  
37 Participants underwent a 2-minute rest phase, 2-minute no resistance warm up, and then 1-  
38 minute steps. Breath-by-breath oxygen consumption ( $VO_2$ ) and carbon dioxide production

1 (VCO<sub>2</sub>) were measured continuously. Participants were blinded to time, wattage, and peak VO<sub>2</sub>  
2 during the test and encouraged to maintain a cadence of ~60 cycles per minute and exercise to  
3 their maximum ability, with the test stopped prematurely for severe hypertension, relative  
4 hypotension, moderate to severe angina, ventricular tachycardia or couplets, or ischemic  
5 changes. Reason for stopping and exertional symptoms were recorded. Exercise effort was  
6 assessed by Borg Scale and respiratory exchange ratio (RER). Anaerobic threshold was  
7 determined manually by the exercise physiologist using the slope method.

#### 8 *Classification of CPET Limitations*

9 We considered ventilatory limitation if rest spirometry was abnormal, tidal volume did not  
10 double over baseline reaching at least 50% of FVC, breathing reserve was <30%, dead space  
11 ratio (V<sub>D</sub>/V<sub>T</sub>) was >0.2, or desaturation occurred. We classified participants as having a cardiac  
12 limitation if there were ischemic ECG changes, the oxygen pulse was reduced and plateaued  
13 early, AT occurred at less than 40% of predicted maximal VO<sub>2</sub>, and if ventilatory efficiency  
14 slope (VE/VCO<sub>2</sub>) was <32. We considered exercise limitation to be likely due to deconditioning,  
15 obesity or impaired gas exchange if exercise capacity was reduced without cardiac or ventilatory  
16 limitation.

17

1 **Supplemental Table 1: Symptom pattern by individual symptoms**

	Prior to COVID (excluded)	Never reported	Reported at 1 <sup>st</sup> visit but not 2 <sup>nd</sup> visit	Reported at 2 <sup>nd</sup> visit but not first visit	Reported at both visits
Any symptom (including fatigue)	n/a	15	7	5	33
Chest pain, dyspnea, or palpitations	n/a	20	9	8	23
Chest pain	1	41	3	8	7
Dyspnea	1	30	9	3	17
Palpitations	4	32	5	8	11
Fatigue	2	20	7	11	20

2 **Supplemental Table 1 Legend:** Trajectory of Symptoms by specific symptoms and whether they were present prior  
 3 to COVID-19, never reported, reported at first visit and resolved prior to second visit, developed after the first visit,  
 4 or were persistent. Note that those with symptoms prior to COVID are excluded for individual symptoms.

5

1 **Supplemental Table 2. Additional CPET parameters including resting echocardiogram and spirometry**

	Symptoms (n=37)	No Symptoms (n=19)	OR (95%CI; p value)
<b>Additional CPET Parameters</b>			
VO <sub>2</sub> AT, ml/kg/min	10.9 (9.4, 13.1)	13.6 (11.5, 17.4)	0.94 (0.81 to 1.10; p=0.49)
VO <sub>2</sub> AT % Predicted pVO <sub>2</sub>	56.5 ± 11.2	50.8 ± 10.0	1.05 (0.97-1.13; p=0.21)
Weber Class			p=0.16
A (pVO <sub>2</sub> >20)	22 (61%)	17 (89%)	Ref
B (pVO <sub>2</sub> 16-20)	8 (22%)	1 (5%)	7.2 (0.6-89)
C (pVO <sub>2</sub> 10-16)	7 (19%)	1 (5%)	6.5 (0.41-103)
Rest Respiratory Rate	17.2 ± 4.7	14.6 ± 6.5	1.14 (0.99-1.31; p =0.07)
Tidal Volume at Peak (% FVC)	51.7±9.1	57.1±12.1	0.95 (0.88-1.03; p=0.19)
Dead Space at Peak (% V <sub>T</sub> )	17.6±3.7	16.1±2.9	1.27 (0.97-1.68; p=0.08)
Vent. Class <sup>a</sup>			
I	23 (72%)	12 (75%)	
II	9 (28%)	4 (25%)	1.55 (0.31-7.72; p=0.59)
<b>Rate Pressure Product, mmHg*bpm</b>	<b>25469± 7023</b>	<b>29712± 4088</b>	<b>1.29 per -1000 (1.01 to 1.40; p=0.04)</b>
<b>Rest Echocardiographic Parameters</b>			
Left Ventricular Ejection Fraction, %	64.9±5.4	65.3±5.0	0.96 (0.84 to 1.08; p=0.49)
LV Diastolic Function			p=0.08
Indeterminate	6 (17%)	1 (5%)	
Mild	5 (14%)	1 (5%)	6.9 (0.62-75.8)
LV Strain, %	-20.0±2.6%	-19.7±1.9%	1.01 (0.77 to 1.32; p=0.96)
RV Strain, %	-24.6±5.5%	-23.9±3.3%	0.99 (0.85-1.15; p=0.90)
TAPSE, cm	2.29±0.38	2.28±0.23	1.01 per -10mm (0.85-1.21; p=0.91)
Pulmonary Artery Pressure, mm Hg	24.3±4.6	21.6±2.0	1.36 (1.02 to 1.81; p=0.04)
Pericardial Effusions	3 (8%)	0	n/a
<b>Rest Spirometry</b>			
Forced Vital Capacity, L	3.8±1.0	4.1±0.6	0.82 (0.32-2.07; p=0.67)
Forced Vital Capacity, % Pred	97±17	101±12	0.97 (0.93-1.02; p=0.26)
Forced Expiratory Volume in 1 second, % Pred	102±18	100±12	1.01 (0.97-1.05; p=0.64)
FEV <sub>1</sub> /FVC, % Pred	104±10	101±5	1.12 (1.01-1.25; p=0.03)
Slow Vital Capacity, % Pred	100±16	104±16	0.99 (0.95-1.03; p=0.55)
Inspiratory Capacity, % Pred	104±27	110±25	0.98 (0.95-1.01; p=0.18)
Maximum Voluntary Ventilation (measured), L/min	130±39	139±28	1.00 (0.98-1.03; p=0.90)

Maximum Voluntary Ventilation, % Pred	105±25	104±17	1.00 (0.97-1.03; p=0.96)
---------------------------------------	--------	--------	--------------------------

1 **Supplemental Table 2 Legend:** Echocardiographic parameters by cardiopulmonary symptom status at echo visit  
2 (median 6 months). Spirometry was performed at the time of CPET (median 18 months). Odds ratios are adjusted  
3 for age, sex, time since SARS-CoV-2 infection, BMI, hospitalization for COVID-19; no change in sensitivity  
4 analysis additionally adjusting for medical history. Mild diastolic dysfunction and indeterminate were combined due  
5 to small numbers and non-convergence of the model. Abbreviations: AT=Anaerobic threshold; bpm=beats per  
6 minute; FVC=Forced Vital Capacity; HR=heart rate; DBP=diastolic blood pressure; MVV=maximal voluntary  
7 ventilation; SBP=systolic blood pressure;  $V_D/V_T$ =Dead space ratio;  $V_E$  = minute ventilation;  $VCO_2$ =carbon dioxide  
8 production;  $pVO_2$ =peak oxygen consumption ( $VO_2$ ); Vent=Ventilatory

9

1 **Supplemental Table 3. Differences in Peak VO<sub>2</sub> by Different Means of Classifying Symptoms**

		Symptom Present	Symptom Absent	Adjusted Difference
Dyspnea, Chest Pain, Palpitations, or Fatigue at Visit 2 (n=27)	<b>VO<sub>2</sub> (ml/kg/min)</b>	<b>22.7±8.1</b>	<b>29.6±7.0</b>	<b>-5.2 (-8.3 to -2.1; p=0.001)</b>
	<b>VO<sub>2</sub>, % predicted</b>	<b>92 ± 22</b>	<b>107 ± 22</b>	<b>-17 (-30 to -4; p=0.01)</b>
Dyspnea, Chest Pain, or Palpitations at Visit 2 (n=30)	VO <sub>2</sub> (ml/kg/min)	23.3 ± 8.7	27.0 ± 7.8	-2.8 (-6.2 to 0.6; p=0.10)
	VO <sub>2</sub> , % predicted	95 ± 23	100 ± 23	-6 (-20 to 7, p=0.36)
Self-Reported Reduced Exercise Capacity at Visit 2 (n=31)	VO <sub>2</sub> (ml/kg/min)	24.7 ± 8.6	25.5 ± 8.3	-0.9 (-4.1 to 2.3; p=0.59)
	VO <sub>2</sub> , % predicted	94 ± 23	101 ± 23	-7.9 (-20 to 5; p=0.21)
Persistent (n=32) vs Never Symptoms (n=13)	<b>VO<sub>2</sub> (ml/kg/min)</b>	<b>22.7 ± 8.5</b>	<b>29.4 ± 8.4</b>	<b>-5.9 (-9.8 to -2.0; p=0.004)</b>
	VO <sub>2</sub> , % predicted	94 ± 23	110 ± 23	-16 (-32 to 0.4; p=0.06)
Symptoms at Visit 1, median 6 months (n= 31)	VO <sub>2</sub> (ml/kg/min)	23.0 ± 8.4	27.6 ± 7.9	-2.9 (-6.3 to 0.5; p=0.10)
	VO <sub>2</sub> , % predicted	95 ± 23	100 ± 23	-3.3 (-17 to 10; p=0.63)

2

3 **Supplemental Table 3 Legend:** Sensitivity analysis of peak VO<sub>2</sub> (ml/kg/min and % predicted) using different  
 4 symptom definitions to classify participants. N listed for the number with that symptom finding.


1 **Supplemental Table 4: Heart Rate Parameters by Chronotropy and Exercise Capacity**

Measure		Value, mean±SD	Adjusted Difference (95%CI; p value)
CPET Peak HR During Exercise, bpm	CI	119±14	-43 (-50 to -36; p<0.001)
	Reduced HR	135±12	-29 (-31 to -24; p<0.001)
	Normal	170±13	
CPET Peak HR, %Age Predicted Max	CI	73±5	-27 (-32 to -21; p<0.001)
	Reduced HR	84±3	-17 (-20 to -14; p<0.001)
	Normal	100±5	
CPET AHRR, %	CI	48±7	-49 (-56 to -42; p<0.001)
	Reduced HR	65±10	-34 (-41 to -27; p<0.001)
	Normal	99±10	
CPET HR Recovery at 1 minute, bpm	CI	9.1±6.1	-7.9 (-15.3 to -0.4; p=0.04)
	Reduced HR	10.9±8.3	-4.5 (-11.6 to 2.7; p=0.21)
	Normal	17.1±8.5	
Ambulatory Max sinus HR, bpm	CI	129±20	-25 (-39 to -11; p=0.002)
	Reduced HR	145±19	-4.8 (-17 to 8; p=0.43)
	Normal	158±17	
Ambulatory Max HR, % Age Predicted Max	CI	81±12	-10.3 (-19.7 to -0.9; p=0.04)
	Reduced HR	87±14	-2.0 (-13.0 to 9.0; p=0.68)
	Normal	95±7	
Ambulatory AHRR*, %	CI	57±22	-31 (-46 to -16; p=0.001)
	Reduced HR	79±25	-6.0 (-20 to 8.1; p=0.38)
	Normal	90±13	
Ambulatory Minimum HR, bpm	CI	57±16	11.5 (2.4 to 20.6; p=0.02)
	Reduced HR	46±6	1.0 (-4.1 to 6.2; p = 0.68)
	Normal	44±5	
Ambulatory Average HR, bpm	CI	81±13	7.8 (0.2 to 15.4; p=0.05)
	Reduced HR	76±11	2.5 (-6.4 to 10.9; p=0.59)
	Normal	73±6	
Ambulatory HR Variability SDNN	CI	107±37	-62 (-98 to -25; p=0.003)
	Reduced HR	178±73	0 (-62 to 61; p=0.99)
	Normal	167±41	

2 **Supplemental Table 4 Legend.** The first row of each measure is the mean±SD for those with chronotropic  
3 incompetence (“CI”, VO<sub>2</sub> <85%, AHRR<80%, and no alternative findings, n=12); the second row is the mean±SD  
4 for those with a reduced chronotropic response (VO<sub>2</sub> ≥85% and AHRR<80%, n=13) and the third row is those with  
5 peak VO<sub>2</sub> ≥85% and AHRR≥80% (n=23). Those with limited exercise capacity for other reasons were excluded.  
6 Adjusted differences are compared to those with normal exercise capacity and heart rate response during exercise.  
7 Results were similar whether considering absolute heart rate, percent of age predicted, or adjusted heart rate reserve  
8 for both CPET and ambulatory measurements. Ambulatory adjusted heart rate reserve uses (max sinus heart rate –  
9 average heart rate)/(220-age-average heart rate). Abbreviations: HR=heart rate, bpm=beats per minute,  
10 CI=chronotropic incompetence, AHRR=adjusted heart rate reserve, SDNN=standard deviation n-to-n.

11

1 **Supplemental Figure 1. Cardiac Rhythms During Button Pushes (n=38)**



2

3 **Supplemental Figure 1 Legend:** Individual participant analysis of number of button pushes and  
4 associated rhythm with each participant on the x axis and the number of times that individual pushed the  
5 symptom button on the y axis with each identified rhythm coded by color. Most button pushes were  
6 associated with sinus rhythm or sinus tachycardia, with supraventricular ectopy (premature atrial  
7 contractions) present among a few individuals especially the 3 with the most button pushes.

8